recipi
allohsct
differ
report
incid
due
part
asymptomat
subclin
manifest
viral
infect
chang
epidemiolog
virus
well
differ
diagnost
method
till
largesampl
epidemiolog
data
overal
incid
viral
infect
absent
recipi
allohsct
limit
data
show
commun
acquir
respiratori
virus
carv
herpesvirus
common
pathogen
among
caus
carv
respiratori
tract
infect
preponder
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
report
follow
influenza
viru
human
metapneumoviru
hmpv
herpesviru
famili
incid
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
infect
well
cytomegaloviru
cmv
diseas
significantli
decreas
effect
prophylaxi
report
human
herp
viru
hhv
diseas
increas
allohsct
recipi
recipi
allohsct
viral
infect
opportunist
close
relat
immun
statu
thu
factor
influenc
engraft
immun
reconstitut
potenti
impact
viral
infect
peripher
blood
stem
cell
transplant
associ
fewer
viral
infect
bone
marrow
cord
blood
transplant
due
better
hematopoiet
immun
reconstitut
compar
hlamatch
relat
transplant
hlamismatch
relat
unrel
transplant
increas
risk
viral
infect
immun
reconstitut
delay
intensifi
gvhd
prophylact
strategi
use
atg
gvhd
may
delay
immun
reconstitut
consid
independ
risk
factor
viral
infect
addit
factor
serolog
statu
donor
recipi
transplant
well
age
recipi
may
also
affect
incid
viral
infect
exampl
cmvseroneg
recipi
receiv
graft
cmvseroposit
donor
high
risk
cmv
diseas
children
highrisk
popul
carv
infect
gener
diagnosi
viral
diseas
immunocompet
individu
base
clinic
manifest
laboratori
examin
definit
diagnosi
requir
detect
specif
viru
specimen
obtain
involv
tissu
secret
well
blood
even
histopatholog
evid
howev
definit
diagnosi
frequent
unnecessari
unavail
due
risk
associ
invas
procedur
eg
infect
bleed
thu
stratifi
diagnosi
viral
infect
diseas
base
diagnost
evid
recommend
clinic
manifest
viral
diseas
immunocompromis
individu
includ
transplant
recipi
may
differ
immunocompet
popul
instanc
fever
alway
occur
dissemin
diseas
common
meanwhil
viral
diseas
gener
occur
subsequ
transplant
complic
bacteri
fungal
infect
exampl
cmv
gastrointestin
diseas
particularli
difficult
diagnos
frequent
present
togeth
gut
gvhd
diarrhea
symptom
two
transplant
complic
therefor
recipi
allohsct
diagnosi
viral
diseas
mainli
depend
laboratori
examin
laboratori
diagnost
method
mainli
includ
viral
cultur
serolog
test
antigen
nucleic
acid
detect
tabl
show
common
method
use
diagnosi
viral
infect
golden
standard
diagnosi
viral
diseas
find
specif
histopatholog
featur
detect
viru
involv
tissu
howev
biopsi
often
infeas
allohsct
recipi
consid
viral
diseas
occur
earli
stage
transplant
concomit
thrombocytopenia
unstabl
vital
sign
viral
cultur
unsuit
earli
diagnosi
routin
take
day
week
requir
specif
cell
line
serolog
test
requir
find
progress
increas
antibodi
identifi
recent
infect
unfortun
transplant
recipi
usual
unabl
mount
suffici
antibodi
immunosuppress
therefor
serolog
less
help
clinic
decis
recipi
allohsct
techniqu
antigen
detect
includ
fluoresc
antibodi
assay
enzym
immunoassay
rapid
diagnost
method
result
avail
within
hour
limit
method
poor
sensit
compar
molecular
techniqu
applic
pcr
techniqu
detect
viral
nucleic
acid
rapidli
develop
viral
diagnost
theori
viru
potenti
detect
pcr
realtim
quantit
pcr
rqpcr
replac
tradit
gelbas
pcr
reflect
chang
viral
load
avail
modern
diagnost
tool
facilit
earli
diagnosi
time
intervent
viral
infect
current
diagnosi
viral
infect
recipi
allohsct
mainli
reli
pcrbase
method
investig
new
uncommon
pathogen
electron
microscopi
viral
cultur
use
although
biopsi
aforement
problem
risk
still
requir
diagnosi
specif
viral
diseas
ebvassoci
posttranspl
lymphoprolif
disord
ptld
although
multipl
strategi
use
treatment
viral
diseas
remain
rather
challeng
agent
avail
efficaci
recipi
allohsct
immunotherapeut
strategi
restor
virusspecif
immun
reduc
immunosuppress
dli
ex
vivo
gener
virusspecif
ctl
advoc
treatment
viral
diseas
howev
reduc
immunosuppress
unfeas
mani
patient
due
potenti
risk
gvhd
dli
limit
unavail
stem
cell
donor
risk
exacerb
gvhd
note
adopt
cellular
therapi
proven
efficaci
virus
cmv
ebv
adenoviru
earli
intervent
dramat
influenc
upon
surviv
may
reduc
extent
perman
injuri
survivor
exampl
patient
carv
infect
treatment
effect
start
prior
develop
lower
respiratori
tract
infect
lrti
respiratori
failur
data
show
patient
ebv
fever
without
tissu
involv
better
treatment
respons
endorgan
diseas
ptld
sinc
specif
therapi
limit
sever
antivir
agent
prevent
viral
infect
crucial
reduc
incid
mortal
viral
diseas
accord
differ
period
transplant
strategi
might
divid
prophylaxi
pretransplant
transplant
posttransplant
transplant
select
virusseroneg
stem
cell
donor
seroneg
recipi
decreas
viru
load
virusseroposit
donor
recipi
consid
transplant
strategi
condit
gvhd
prophylaxi
chosen
prudent
minim
delay
immun
reconstitut
transplant
prophylaxi
perform
throughout
risk
period
preengraft
gvhd
incid
hsv
vzv
infect
decreas
lower
recipi
allohsct
receiv
antivir
prophylaxi
throughout
risk
period
preemptiv
therapi
reactiv
latent
virus
cmv
ebv
demonstr
reduc
progress
viral
diseas
vaccin
vzv
vaccin
seem
use
prevent
correspond
viral
infect
influenza
viru
vaccin
suggest
given
recipi
prior
influenza
season
respiratori
diseas
hsct
mainli
caus
carv
virus
herpesvirus
adenoviru
may
also
result
respiratori
infect
major
patient
present
upper
respiratori
infect
patient
may
progress
lower
respiratori
infect
mortal
incid
respiratori
diseas
allohsct
rang
incid
viral
pneumonia
typic
clinic
manifest
includ
fever
cough
myalgia
dyspnea
import
symptom
viral
pneumonia
carv
infect
show
pronounc
season
exampl
rsv
influenza
viru
reach
peak
incid
winter
spring
carv
may
also
result
epidem
outbreak
ward
herpesviru
pneumonia
usual
caus
reactiv
latent
virus
occur
sever
immunosuppress
earli
period
transplant
gvhd
immunocompet
individu
herpesvirus
frequent
pathogen
sporad
viral
encephalitismening
retrospect
studi
schmidthieb
et
al
show
viral
enceph
mainli
caus
human
herp
viru
hhv
follow
ebv
hsv
jc
viru
cmv
vzv
recipi
allohsct
data
show
herpesvirusassoci
enceph
mainli
caus
ebv
follow
hsv
cmv
vzv
recent
enceph
caus
adenoviru
increas
incid
viral
enceph
allohsct
retrospect
studi
result
reveal
incid
herpesvirusesassoci
encephalitismening
recipi
allohsct
viral
encephalitismening
usual
occur
within
day
posttransplant
clinic
manifest
viral
encephalitismening
divers
includ
fever
chang
conscious
seizur
palsi
brain
nerv
psychiatr
disord
mening
irrit
common
compar
healthi
popul
mortal
viral
encephalitismening
rang
depend
viru
type
time
diagnosi
treatment
rotaviru
noroviru
consid
main
caus
viral
gastroenter
current
adenoviru
cmv
increasingli
recogn
import
pathogen
viral
gastroenter
recipi
allohsct
astrovirusassoci
gastroenter
usual
occur
children
rare
observ
recipi
allohsct
data
avail
incid
viral
gastroenter
allohsct
van
kraaij
et
al
document
hsct
recipi
includ
allo
autohsct
develop
viral
gastroenter
fortun
mortal
caus
rotaviru
norovirusrel
gastroenter
rare
common
clinic
manifest
viral
gastroenter
diarrhea
follow
vomit
nausea
rotaviru
noroviru
infect
season
peak
incid
winter
patient
acquir
virus
commun
median
onset
time
adenoviru
cmv
gastroenter
day
transplant
usual
associ
acut
gvhd
viral
hepat
third
caus
hepat
impair
recipi
allohsct
usual
occur
month
transplant
frequent
pathogen
viral
hepat
hepat
b
viru
hbv
hepat
c
viru
hcv
besid
virus
cmv
hsv
may
also
result
hepat
hepat
b
c
caus
either
viru
reactiv
blood
transmiss
sinc
carriag
rate
hbv
hcv
vari
differ
region
incid
viral
hepat
vari
increas
viru
load
blood
valuabl
diagnosi
note
diagnosi
viral
hepat
base
exclus
transplant
complic
eg
sinusoid
obstruct
syndrom
so
gvhd
attribut
effect
prophylaxi
antivir
treatment
mortal
hepat
b
c
low
posttranspl
cystiti
usual
present
hemorrhag
cystiti
hc
accord
onset
time
hc
divid
earlyonset
hc
within
hour
condit
lateonset
hc
occur
hour
earlyonset
hc
often
due
toxic
condit
regimen
cyclophosphamid
report
patient
develop
lateonset
hc
transplant
lateonset
hc
consid
relat
reactiv
latent
bk
viru
bkv
associ
remain
controversi
studi
suggest
acut
gvhd
might
increas
risk
hc
recent
adenoviru
cmv
suggest
associ
lateonset
hc
ptld
lifethreaten
complic
follow
allohsct
approxim
ptld
result
ebvdriven
b
cell
prolifer
poorli
control
weaken
immun
respons
recent
data
implic
cmv
might
contribut
develop
ptld
incid
ptld
vari
depend
number
risk
factor
recipi
allohsct
ptld
occur
within
year
posttransplant
reach
peak
incid
within
month
isol
nodal
involv
common
present
patient
present
extranod
involv
isol
extranod
involv
rare
clinic
present
ptld
depend
locat
degre
organ
involv
ptld
extranod
involv
usual
poor
outcom
mortal
ptld
delay
diagnosi
treatment
associ
high
mortal
bone
marrow
suppress
common
recipi
allohsct
graft
failur
fatal
complic
transplant
sever
virus
cmv
ebv
adenoviru
recogn
caus
bone
marrow
suppress
graft
failur
diagnosi
virusassoci
graft
failur
base
pancytopenia
bone
marrow
hypoplasia
detect
viru
togeth
exclus
gvhd
reject
relaps
healthi
popul
histori
infect
infect
common
primari
infect
viru
becom
latent
neuron
cell
histor
hsvseroposit
patient
develop
reactiv
allohsct
without
antivir
prophylaxi
fortun
incid
hsv
reactiv
decreas
prophylact
acyclovir
hsv
caus
spectrum
diseas
herp
oesophag
bone
marrow
suppress
respiratori
tract
diseas
hepat
enceph
recipi
allohsct
due
high
rate
hsv
reactiv
prophylact
oral
acyclovir
administ
routin
allohsct
recipi
intraven
acyclovir
consid
patient
poor
drug
absorpt
valacyclovir
altern
prophylact
agent
good
bioavail
acyclovir
recommend
therapi
sever
mucocutan
viscer
hsv
diseas
transplant
recipi
valaciclovir
famciclovir
consid
altern
less
seriou
manifest
hsv
diseas
recommend
drug
acyclovirresist
hsv
foscarnet
cidofovir
might
effect
treat
hsv
infect
resist
acyclovir
foscarnet
varicella
caus
primari
vzv
infect
common
childhood
diseas
primari
infect
vzv
establish
latenc
dorsal
root
ganglia
immunocompet
host
reactiv
vzv
result
herp
zoster
recipi
allohsct
vzv
also
import
caus
viral
enceph
vzv
immun
advoc
recipi
without
histori
varicella
varicella
vaccin
show
safe
children
leukemia
data
avail
transplant
recipi
besid
vaccin
vzvseroneg
individu
may
contact
patient
transplant
done
zoster
immun
globulin
zig
varicellazost
immun
globulin
vzig
passiv
antibodi
prophylaxi
seroneg
recipi
exposur
varicella
acyclovir
valacyclovir
prophylaxi
proven
effect
sever
trial
antivir
therapi
acyclovir
recommend
treatment
vzv
infect
acyclovir
shown
reduc
progress
dissemin
vzv
infect
treatment
brivudin
famiciclovir
effect
immunocompromis
popul
foscarnet
cidofovir
altern
agent
acyclovirresist
vzv
infect
cmv
infect
healthi
individu
establish
latenc
peripher
blood
monocyt
tissu
macrophag
till
cmv
remain
one
import
virus
caus
death
recipi
allohsct
cmvassoci
endorgan
diseas
includ
pneumonia
enter
hepat
retin
enceph
cmv
syndrom
defin
cmvassoci
fever
without
sign
cmv
endorgan
diseas
major
cmv
infect
caus
reactiv
viru
usual
occur
within
month
posttransplant
approxim
cmvseroposit
recipi
develop
cmv
reactiv
patient
develop
cmv
diseas
without
intervent
preemptiv
therapi
base
cmv
antigenemia
dnaemia
significantli
reduc
develop
cmv
diseas
allohsct
patient
howev
mortal
cmv
diseas
even
treatment
diagnosi
cmv
infect
includ
cmv
viremia
cmv
syndrom
cmv
endorgan
diseas
histor
cmv
antigen
detect
wide
use
diagnosi
cmv
infect
recent
pcr
replac
antigenemia
assay
prefer
diagnost
method
due
higher
sensit
preemptiv
therapi
base
cmv
viremia
becom
standard
prevent
cmv
diseas
transplant
firstlin
preemptiv
therapi
ganciclovir
minimum
durat
week
depend
whether
cmv
detect
end
cours
main
side
effect
ganciclovir
bone
marrow
suppress
result
increas
bacteri
fungal
infect
valganciclovir
altern
good
bioavail
foscarnet
cidofovir
secondlin
prophylact
agent
consid
drugassoci
toxic
ganciclovir
firstlin
treatment
cmv
diseas
recommend
therapi
cmv
pneumonia
combin
intraven
ganciclovir
high
dose
immun
globulin
view
toxic
effect
rate
cidofovir
foscarnet
use
secondlin
therapi
cmv
diseas
ganciclovir
resist
uncommon
usual
mediat
mutat
gene
cidofovir
use
treatment
cmv
diseas
resist
ganciclovir
foscarnet
effect
rate
sinc
known
specif
immun
respons
cmv
import
control
reactiv
cmvspecif
ctl
use
prophylaxi
treatment
cmv
viremia
sever
studi
leen
et
al
report
respons
rate
cmvspecif
ctl
treatment
cmv
diseas
allohsct
approxim
healthi
adult
infect
ebv
primari
infect
ebv
latent
b
cell
primari
ebv
infect
reactiv
usual
induc
asymptomat
infect
infecti
mononucleosi
immunocompet
peopl
howev
ebv
result
spectrum
diseas
recipi
allohsct
rang
fever
endorgan
diseas
pneumonia
encephalitismyel
hepat
ptld
among
diseas
ptld
common
data
show
cumul
incid
ebv
diseas
recipi
allohsct
ptld
incid
ebv
diseas
usual
caus
reactiv
latent
viru
allohsct
transplant
recipi
develop
ebv
reactiv
depend
differ
risk
factor
recipi
diagnosi
ebv
infect
includ
ebv
viremia
probabl
endorgan
diseas
proven
endorgan
diseas
well
ptld
sinc
rapid
increas
ebvdna
load
blood
consid
relat
subsequ
ebv
diseas
routin
monitor
ebv
viral
load
necessari
transplant
preemptiv
therapi
base
ebvdna
load
blood
risk
factor
ebv
diseas
yield
good
result
preemptiv
therapi
develop
mainli
two
direct
adopt
cellular
therapi
ebvspecif
ctl
bcell
deplet
monoclon
antibodi
ebvspecif
ctl
demonstr
effect
prevent
ebv
diseas
sever
studi
product
ctl
requir
time
besid
reduct
immunosuppress
ideal
preemptiv
therapi
frequent
avail
due
risk
gvhd
rituximab
easili
avail
shown
littl
toxic
base
rituximab
recommend
prefer
preemptiv
therapi
follow
reduct
immunosuppres
ebvspecif
ctl
european
guidelin
therapeut
strategi
ebv
diseas
includ
antiviru
restor
cell
respons
clearanc
ebv
infect
cell
antivir
agent
eg
acyclovir
ganciclovir
reduc
ebv
replic
activ
ptld
presum
viral
thymidin
kinas
express
low
lytic
phase
lack
latenc
recent
novel
agent
arginin
butyr
induc
ebv
thymidin
kinas
transcript
shown
vitro
render
latent
infect
ebvimmort
b
cell
suscept
ganciclovir
treatment
restor
tcell
reactiv
includ
reduct
immunosuppress
adopt
cellular
therapi
ctl
dli
monoclon
antibodi
rituximab
use
clear
ebvinfect
b
cell
accord
european
guidelin
rituximab
recommend
highest
prioriti
treatment
ptld
firstlin
treatment
includ
reduc
immunosuppress
ebvctl
dli
chemotherapi
recommend
secondlin
therapi
respons
rate
rituximab
monotherapi
report
wherea
relaps
rate
compar
rituximab
adopt
cellular
immunotherapi
higher
respons
rate
fewer
relaps
nevertheless
util
adopt
cellular
therapi
limit
aforement
disadvantag
time
facil
requir
ctl
product
well
potenti
risk
gvhd
caus
dli
chemotherapi
report
induc
remiss
ptld
patient
signific
treatmentrel
mortal
relaps
rate
therefor
era
rituximab
chemotherapi
bare
use
unless
ptld
combin
rituximab
date
random
trial
compar
efficaci
rituximab
alon
rituximab
combin
chemotherapi
trapp
et
al
suggest
sequenti
firstlin
treatment
rituximab
follow
chemotherapi
efficaci
firstlin
rituximab
monotherapi
follow
chemotherapi
progress
relaps
studi
introduc
sequenti
therapeut
strategi
rituximabbas
treatment
follow
adopt
cellular
immunotherapi
result
reveal
strategi
might
elev
respons
rate
decreas
relaps
rate
besid
strategi
might
overcom
drawback
long
time
frame
product
ebvctl
reduc
risk
gvhd
caus
dli
remain
matter
discuss
whether
histolog
subtyp
ptld
affect
outcom
rituximabbas
treatment
prognosi
ptld
extranod
multiorgan
involv
dismal
compar
isol
nodal
involv
studi
suggest
intrathec
rituximab
efficaci
ptld
cn
involv
therapeut
option
includ
local
radiotherapi
oper
mainli
patient
signific
compress
symptom
clinic
data
ebv
fever
endorgan
diseas
quit
limit
rituximab
seem
efficaci
treat
ebv
fever
respons
rate
treatment
strategi
ebv
endorgan
diseas
similar
ptld
howev
efficaci
rituximab
monotherapi
patient
endorgan
diseas
seem
poorer
ptld
approxim
recipi
develop
reactiv
transplant
diseas
includ
enceph
interstiti
lung
diseas
delay
engraft
two
smallsampl
studi
suggest
ganciclovir
might
effect
prevent
reactiv
allohsct
recipi
howev
wide
accept
prophylact
strategi
recommend
consid
drug
toxic
low
incid
diseas
ganciclovir
foscarnet
report
effect
diseas
infectionreactiv
infrequ
recipi
allohsct
littl
inform
diseas
avail
therefor
prophylaxi
treatment
infect
remain
unclear
recogn
caus
kaposi
sarcoma
human
immunodefici
viru
hiv
infect
patient
infect
rare
recipi
allohsct
usual
result
nonmalign
diseas
hepat
bone
marrow
suppress
current
clinic
data
prevent
treatment
diseas
allohsct
base
case
report
cessat
immunosuppress
foscarnet
use
treatment
efficaci
requir
studi
rsv
one
common
respiratori
pathogen
seri
includ
hsct
recipi
limit
data
avail
prevent
rsv
infect
studi
treat
upper
respiratori
tract
diseas
effect
reduc
progress
pneumonia
improv
outcom
report
confirm
result
aerosol
ribavirin
without
rsvspecif
immunoglobulin
intraven
immunoglobulin
use
treat
rsv
pneumonia
surviv
approxim
treatment
start
respiratori
failur
associ
improv
outcom
intraven
ribavirin
less
effect
increas
side
effect
efficaci
palivizumab
rsvspecif
monoclon
antibodi
hsct
recipi
well
defin
piv
infect
occur
throughout
year
highest
incid
juli
septemb
prophylact
therapeut
strategi
piv
infect
remain
matter
discuss
largesampl
retrospect
analysi
suggest
aerosol
ribavirin
without
intraven
immunoglobulin
improv
outcom
piv
pneumonia
elizaga
et
al
document
effect
rate
aerosol
ribavirin
therapi
treatment
upper
tract
infect
wherea
patient
piv
pneumonia
surviv
prevent
influenza
transplant
european
guidelin
recommend
vaccin
perform
hsct
recipi
season
influenza
vaccin
meanwhil
vaccin
healthcar
worker
close
contact
hsct
recipi
advoc
prophylaxi
oseltamivir
seem
use
exposur
period
influenza
circul
inhibitor
amantadin
rimantidin
longer
use
treatment
due
widespread
resist
neuraminidas
inhibitor
oral
oseltamivir
inhal
zanamivir
wide
use
therapeut
agent
influenza
effect
rate
intervent
initi
within
hour
symptom
onset
associ
reduc
risk
pneumonia
need
intens
care
present
respiratori
infect
hsct
caus
hcov
hmpv
hrhv
increasingli
recogn
recent
studi
hcov
found
recipi
within
month
hsct
includ
lrti
hmpv
hrhv
found
recipi
respect
efficaci
prevent
treatment
hmpv
infect
well
describ
ribavirin
andor
intraven
immunogloblin
use
treat
hmpv
pneumonia
sever
studi
efficaci
defin
prevent
treatment
strategi
hrhv
limit
lack
antivir
agent
clinic
trial
recommend
prophylaxi
treatment
due
absenc
effect
antivir
agent
appropri
clinic
studi
adenoviru
increasingli
recogn
import
pathogen
immunocompromis
individu
especi
recipi
allohsct
adenoviru
infect
may
aris
either
reactiv
latent
viru
acquisit
commun
contrari
selflimit
infect
immunocompet
individu
adenoviru
caus
lethal
endorgan
system
diseas
immunocompromis
patient
incid
adenoviru
infect
rang
adult
allohsct
recipi
half
patient
develop
adenovirusassoci
diseas
adenoviru
diseas
includ
respiratori
tract
diseas
gastroenter
enceph
myocard
nephriti
multipl
organ
involv
mortal
report
high
adenoviru
pneumonia
dissemin
diseas
pcr
standard
diagnost
method
adenoviru
infect
diagnost
approach
includ
viral
cultur
antigen
detect
strict
isol
hygien
measur
advoc
patient
shed
adenoviru
prevent
horizont
transmiss
nosocomi
outbreak
bordigoni
et
al
suggest
cidofovir
dli
seem
encourag
approach
prevent
adenoviru
diseas
wherea
ribavirin
vidarabin
ineffect
efficaci
ribavirin
controversi
treatment
adenoviru
diseas
sever
studi
document
cidofovir
efficaci
adenoviru
consid
insuffici
immun
respons
control
adenoviru
reactiv
patient
adenovirusspecif
ctl
seem
promis
therapi
leen
et
al
report
effect
rate
adenovirusspecif
ctl
recipi
allohsct
addit
reduct
immunosuppress
recommend
prophylaxi
treatment
possibl
rotaviru
noroviru
import
pathogen
viral
gastroenter
incid
rotaviru
infect
hsct
recipi
death
rare
antigen
detect
well
pcr
use
diagnosi
rotaviru
infect
present
noroviru
caus
gastroenter
allohsct
well
recogn
pediatr
hsct
recipi
incid
norovirusassoci
gastroenter
report
norovirusassoci
mortal
observ
detect
noroviru
rna
pcr
main
diagnost
evid
till
littl
inform
avail
prevent
treatment
rotaviru
noroviru
hsct
popul
oral
immunoglobulin
nitazoxanid
use
studi
among
hepat
virus
hbv
hcv
import
caus
hepat
impair
recipi
allohsct
hepat
virusposit
donor
avoid
altern
exist
hbvneg
recipi
pretranspl
vaccin
hbvspecif
immun
globulin
consid
donor
hbv
surfac
antigen
posit
hbvposit
recipi
administr
antivir
agent
ie
lamivudin
famciclovir
entecavir
adefovir
pre
posttransplant
advoc
reduc
hbv
replic
administr
ribavirin
interferon
consid
decreas
clear
viral
load
transplant
donor
recipi
hcv
posit
interferon
without
ribavirin
use
treatment
hepat
c
jc
viru
jvc
belong
polyomaviru
famili
known
pathogen
progress
multifoc
leukoencephalopathi
pml
patient
hiv
infect
report
pml
quit
rare
recipi
allohsct
current
treatment
prevent
jcv
hsct
recipi
remain
unclear
treatment
consist
reduct
immunosuppress
cidofovir
serotoninreuptak
inhibitor
well
jcvspecif
ctl
infus
demonstr
produc
favor
clinic
outcom
mention
bkv
member
polyomaviru
famili
one
caus
hc
allohsct
recipi
report
ciprofloxacin
fluoroquinolon
may
use
prevent
bkv
reactiv
cidofovir
use
treatment
bkvassoci
hc
viral
diseas
import
complic
hsct
develop
viral
diagnost
improv
earli
diagnosi
increas
diagnost
rate
newli
discov
uncommon
virus
allohsct
recipi
base
pathogenesi
viral
diseas
prophylaxi
especi
preemptiv
therapi
limit
reactiv
latent
virus
immunotherapeut
strategi
restor
virusspecif
immun
attract
method
treatment
viral
diseas
author
declar
compet
interest
manuscript
deriv
literatur
summar
report
prepar
rl
qfl
author
wrote
manuscript
read
approv
final
version
